Mundipharma
Pingping Ni is an accomplished statistician with extensive experience in the pharmaceutical industry, currently serving as the Head of Oncology SL Statistics at GSK since January 2022. Previously, Pingping Ni held the position of Director and Biometrics Team Lead at AstraZeneca, while also serving as Director and Head of Statistics and Programming at Mundipharma Research Ltd. and Head of Statistics at Mitsubishi Tanabe Pharma Europe Ltd. Additionally, Pingping Ni has held various roles, including Senior Manager of Statistics at Mitsubishi Pharma Europe and Senior Statistician at GSK. The career began as a Statistician at Bayer HealthCare and as a Computer Engineer at the Institute of Computing Technology, Chinese Academy of Sciences. Pingping Ni holds a Ph.D. in Statistics and Probability from Michigan State University and has valuable leadership experience in building high-performing teams, supporting healthcare product development, and integrating modern data science technologies.
This person is not in any teams
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.